Kezar Life Sciences (KZR) Expected to Announce Earnings on Tuesday

Key Points

• Kezar will report Q1 2026 results before the market opens on May 12, 2026, with analysts projecting EPS of ($0.98) and $0.50M in revenue and an earnings call set for May 13 at 4:00 PM ET.
• The company missed the prior quarter (reported ($1.99) EPS vs. a ($1.39) consensus), and analysts expect about ($2) EPS for both the current and next fiscal years.
• Shares traded at about $7.38 (market cap ~$54.41M) with a 52‑week range of $3.53–$7.55; institutional investors own roughly 67.9%, and the company’s lead candidate is the selective immunoproteasome inhibitor KZR‑616 in multiple autoimmune trials.

Kezar Life Sciences (NASDAQ:KZR - Get Free Report) is projected to announce its Q1 2026 results before the market opens on Tuesday, May 12th. Analysts expect the company to announce earnings of ($0.98) per share and revenue of $0.50 million for the quarter. Investors can check the company's upcoming Q1 2026 earning summary page for the latest details on the call scheduled for Wednesday, May 13, 2026 at 4:00 PM ET.

Kezar Life Sciences (NASDAQ:KZR - Get Free Report) last announced its quarterly earnings data on Friday, March 27th. The company reported ($1.99) EPS for the quarter, missing analysts' consensus estimates of ($1.39) by ($0.60). On average, analysts expect Kezar Life Sciences to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Kezar Life Sciences Stock Performance

Kezar Life Sciences stock traded down $0.01 during trading hours on Tuesday, reaching $7.38. 25,281 shares of the stock were exchanged, compared to its average volume of 64,829. The stock has a market cap of $54.41 million, a P/E ratio of -0.96 and a beta of 0.40. Kezar Life Sciences has a 52-week low of $3.53 and a 52-week high of $7.55. The firm's 50 day moving average is $7.06 and its 200 day moving average is $6.49.

Hedge Funds Weigh In On Kezar Life Sciences

A number of large investors have recently modified their holdings of the business. Geode Capital Management LLC raised its stake in shares of Kezar Life Sciences by 4.1% during the 4th quarter. Geode Capital Management LLC now owns 68,167 shares of the company's stock worth $429,000 after buying an additional 2,665 shares in the last quarter. Dimensional Fund Advisors LP raised its stake in shares of Kezar Life Sciences by 14.3% during the 4th quarter. Dimensional Fund Advisors LP now owns 26,543 shares of the company's stock worth $167,000 after buying an additional 3,312 shares in the last quarter. State Street Corp raised its stake in shares of Kezar Life Sciences by 28.4% during the 4th quarter. State Street Corp now owns 27,093 shares of the company's stock worth $170,000 after buying an additional 6,000 shares in the last quarter. Bridgeway Capital Management LLC raised its stake in shares of Kezar Life Sciences by 25.9% during the 4th quarter. Bridgeway Capital Management LLC now owns 51,638 shares of the company's stock worth $325,000 after buying an additional 10,638 shares in the last quarter. Finally, Landscape Capital Management L.L.C. purchased a new position in shares of Kezar Life Sciences in the 3rd quarter valued at about $51,000. 67.90% of the stock is owned by hedge funds and other institutional investors.

About Kezar Life Sciences

Kezar Life Sciences is a clinical-stage biotechnology company focused on the discovery and development of novel small-molecule therapies that modulate the innate immune system. The company's research centers on selective inhibition of the immunoproteasome, a key protein complex involved in antigen processing and secretion of inflammatory cytokines. By targeting this pathway, Kezar aims to address unmet medical needs in autoimmune and inflammatory diseases with high specificity and a favorable safety profile.

The company's lead development candidate, KZR-616, is a selective immunoproteasome inhibitor being evaluated in multiple clinical trials for autoimmune conditions such as systemic lupus erythematosus, lupus nephritis, polymyositis and dermatomyositis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.